By leveraging the Fresh Start Effect at site initiation and shifting from passive training to demonstrated readiness, ...
In today’s ACT Brief, we examine persistent barriers limiting cancer trial participation and emerging approaches to address ...
Understand which barriers to cancer trial participation remain most difficult to overcome, including geography and trial ...
Explore early data from the ACTS program that reveal the volume and types of patient-reported barriers to cancer care and ...
In a new ACT video interview, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American ...
Learn why combining AI-enabled trial matching with transportation, lodging, and financial assistance is essential to turning ...
A structured data ownership model—rooted in ICH GCP principles, supported by MHRA and FDA interpretations, and documented in validated system specifications—will enable sponsors to maintain compliance ...
In today’s ACT Brief, we cover the FDA approval of oral Wegovy based on Phase III OASIS 4 results, recap the most-read ...
Review the performance, engagement, and satisfaction metrics sponsors and CROs should track to determine whether operational ...
Funding uncertainty, legal and political pressures, trade policy shifts, site collaboration strategies, and leadership perspectives were central themes across Applied Clinical Trials’ most-watched ...
Wegovy pill, the first oral GLP-1 for weight loss, is FDA-approved for reducing cardiovascular risks in adults. Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, ...
Persistent recruitment delays, high dropout rates, and missed timelines continue to slow global clinical trials, while data show that sub-Saharan Africa offers a largely untapped opportunity with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback